BioSpace News Archive

Amgen (NASDAQ: AMGN) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York City time, at the end of Monday, March 5, 2018.

WuXi NextCODE, the emerging global standard platform for genomic data, today announced that CEO Hannes Smarason will present at Cowen and Company’s 38th Annual Health Care Conference on Monday, March 12, at 11:30am ET. The conference is being held at the Boston Marriott Copley Place Hotel on March 12-14.

Sweetch, the mobile-health app that helps prevent and improve outcomes in diabetes by encouraging long-term behavioral change, today revealed the outcomes of its clinical trial conducted at Johns Hopkins University.

Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today announced the promotion of Christina Isacson, Ph.D. to chief business officer, and Tony Boitano, Ph.D. to vice president, stem cell biology.

The Silver Storm Wireless Medical Mouse is the only mouse that fully secures patient data and complies with HIPAA regulations via AES128 encryption.

Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that its Afibromer™ Living Therapeutic candidate SIG-003 has been granted an Advanced Therapy Medicinal Product (ATMP) designation by the Committee for Advanced Therapies of the European Medicines Agency.

Audentes Therapeutics Inc. reported its financial results for the fourth quarter and full year ended December 31, 2017 and provided an update on the company’s recent achievements and anticipated upcoming milestones.

Cerus Corporation announced financial results for the fourth quarter and year ended December 31, 2017.

Technavio has announced their latest report on stem cell therapy for multiple sclerosis for the period 2018-2022

Option Care Enterprises, Inc. has been selected by Theratechnologies Inc. as an infusion provider for Trogarzo™ (ibalizumab-uiyk) Injection, an intravenous (IV) infusion for the treatment of multidrug resistant human immunodeficiency virus type 1 (HIV-1) infections.